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 ABSTRACT 
 The objectives of the current study were to evaluate 
the efficacy and field safety of GnRH HCl administered 
at 3 doses in fixed-time artificial insemination (FTAI) 
programs (Ovsynch) in dairy cows. A common protocol 
was conducted at 6 commercial dairies. Between 188 
and 195 cows were enrolled at each site (total enrolled 
= 1,142). Cows had body condition scores ≥2 and ≤4, 
were between 32 to 140 d in milk, and were clinically 
healthy. Within pen and enrollment day (enrollment 
cohort), cows were assigned randomly in blocks of 4 to 
each of 4 treatments: (1) 25 mg of PGF2α on d 7 with 
FTAI 72 ± 2 h later (control); (2) 100 μg of GnRH 
on d 0, d 7 a dose of 25 mg of PGF2α, and the second 
administration of 100 μg of GnRH (T100) administered 
either at 48 ± 2 h (d 9) after PGF2α with FTAI 24 ± 
2 h later or 56 ± 2 h (d 9) after PGF2α and FTAI 17 
± 2 h later; (3) same as T100 with both injections of 
150 μg of GnRH (T150); and (4) same as T100 with 
both injections of 200 μg of GnRH (T200). Three sites 
selected the first option and 3 sites selected the second 
option for the timing of the second injection of all doses 
of GnRH. Cows were observed daily for signs of estrus 
and adverse clinical signs. Cows not returning to estrus 
had pregnancy diagnosis between 42 and 65 d following 
FTAI. Pregnancies per FTAI (P/FTAI) were analyzed 
as a binary variable (1 = pregnant, 0 = not pregnant) 
using a generalized linear mixed model with a bino-
mial error distribution and a logit link function. The 
statistical model included fixed effects for treatment, 
random effects of site, site by treatment, enrollment co-
hort within site, and residual. Parity (first vs. second or 
greater) was included as a covariate. For demonstration 
of effectiveness, α = 0.05 and a 2-tailed test were used. 
Fifty-two cows were removed from the study because of 
either deviation from the protocol, injury, illness, cull-
ing, or death. Among the remaining 1,090 cows, 33.9% 
were primiparous and 66.1% were multiparous. Back-
transformed least squares means for P/FTAI were 17.1, 
27.3, 29.1, and 32.2% for control, T100, T150 and T200, 
respectively. The P/FTAI for each GnRH dose differed 
from that of the control. No differences were detected 
in P/FTAI between GnRH doses. No treatment-related 
adverse events were observed. Mastitis was the most 
frequently observed adverse clinical sign, followed by 
lameness and pneumonia. This study documents the 
efficacy and safety of doses of 100 to 200 μg of GnRH 
as the HCl salt when used in Ovsynch programs. 
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 INTRODUCTION 
 The fixed-time artificial insemination (FTAI) pro-
gram commonly called Ovsynch has been well described 
for use in dairy cattle (Pursley et al., 1995; Schmitt et 
al., 1996; Stevenson et al., 1996, 1999). This program 
consists of administration of GnRH, administration of 
PGF2α 7 d later, and then, generally 48 or 56 h later, 
a second injection of GnRH is administered with FTAI 
24 or 16 h later, respectively. These programs use 100 
μg of GnRH for both injections because this was the 
labeled dose of GnRH in cattle for treatment of ovarian 
follicular cysts, the only label claim for GnRH products 
in the United States at the time these FTAI programs 
were developed. Limited evaluation of other doses of 
GnRH in these FTAI programs has taken place. Leslie 
et al. (2003) evaluated 100 and 200 μg of GnRH, with 
all possible dose combinations for first and second dose, 
in a 48-h Ovsych program and did not detect any over-
all difference in pregnancies to FTAI (P/FTAI) be-
tween treatments with an overall mean of 32%. Fricke 
et al. (1998) evaluated 50 or 100 μg of GnRH diacetate 
tetrahydrate for both administrations in an Ovsynch 
program in dairy cows and did not detect a difference in 
either the ovulation rate to the second dose of GnRH or 
P/FTAI. In general, a dose of 100 μg has been deemed 
acceptable for use in these FTAI programs. 
 Souza et al. (2009), using an ovulation model in dairy 
cows, reported a reduced ovulation rate in response to 
100 μg of GnRH as the HCl salt, relative to ovulation 
rate in response to 100 μg of GnRH diacetate tetra-
hydrate. In contrast, no difference was detected in LH 
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response following administration of the same dose of 
these 2 salts of GnRH. Only one product containing 
GnRH HCl is registered in the United States (Factrel 
injection, Zoetis). All other GnRH products contain 
either the diacetate tetrahydrate or acetate salt. The 
current study was conducted to evaluate the efficacy 
and field safety of the administration of GnRH HCl in 
FTAI programs when both administrations of GnRH 
in the treatment protocol were either 100, 150, or 200 
μg of GnRH. Efficacy was measured as P/FTAI, deter-
mined at 42 to 65 d after FTAI.
MATERIALS AND METHODS
All aspects of this study were performed to meet 
FDA-CVM, Guidance for Industry #85, Good Clini-
cal Practice, VICH GL9, Final Guidance, 9 May 2001, 
and was conducted under the authorization of FDA 
CVM Investigational New Animal Drug Authorization 
011–912. The trial was conducted in a manner consis-
tent with applicable local, state, and federal laws and 
regulations governing humane care of animals on com-
mercial farms under veterinary supervision. The proto-
col was reviewed and approved by the Zoetis Veterinary 
Medicine Research and Development Ethical Review 
Board.
Locations and Animals
The study was conducted from October 2011 to 
April 2012 using a common protocol at each of 6 dairy 
farms producing milk for commerce located in New 
York, Michigan, Minnesota, Colorado, California, and 
Florida. These farms had facilities consistent with com-
mercial operations within their geographical locations. 
At 5 sites, cows were housed in freestall barns with 
central feed alley with or without adjacent dry lots. 
Housing at the remaining site (CO) consisted of dry 
lots. All facilities had feed bunks with head lock-ups 
where observations were conducted and treatments 
were administered. Cows were Holstein at 5 sites and 
either Jersey or Jersey by Holstein cross at the Min-
nesota site. Cows were fed diets designed to meet or 
exceed NRC (2001) requirements for lactating dairy 
cows, and regional feed components were used. Cows 
were milked 3 times daily in herringbone, parallel, or 
rotary parlors.
All cows were subjected to a preenrollment physi-
cal exam and were clinically healthy at the time of 
enrollment. At enrollment cows were at least 32 and 
no more than 140 DIM with a BCS ≥2 and ≤4 using a 
5-point scale. No reproduction products (GnRH, PGF, 
progesterone) had been administered within 20 d before 
enrollment.
Treatments and Experimental Design
The objective was to evaluate the effectiveness, as 
measured by P/FTAI, of each of 3 doses of GnRH HCl 
compared with the control. The study was powered 
(80%) to be able to detect an expected difference of 15 
percentage points between each GnRH HCl dose and 
the control, assuming responses were 15% in control 
and 30% in each GnRH HCl dose, using a 2-sided test 
and α = 0.05. Thus, based on the small difference in 
P/FTAI reported administering 50 or 100 μg of GnRH 
diacetate tetrahydrate in the Ovsynch program (Fricke 
et al. 1998), the current study was not designed to be 
able to detect potentially small differences that may 
occur between the selected doses of GnRH HCl.
Within each dairy, the study was conducted as a ran-
domized complete block design with cows blocked by 
order-of-entry within a pen, without regard to parity. 
At most sites primiparous cows were housed in pens 
separated from multiparous cows. Once cows were de-
clared eligible for enrollment they were entered onto the 
next line of an allotment form previously prepared by 
the sponsor (Zoetis VMRD). Using this allotment form, 
cows (n = 4) were entered in each block, with each of 
the 4 treatments randomized within block. Thus, blocks 
consisted of 4 cows enrolled from the same housing unit 
(pen) on the same enrollment day. An enrollment co-
hort consisted of all cows enrolled in the same pen or 
lot on the same day. Most sites enrolled more than one 
enrollment cohort on each day of enrollment. Incom-
plete blocks were allowed. With the expectation that 
not all cows would complete the study, a minimum of 
188 cows were enrolled at each site, providing 2 blocks 
more than identified as needed by power calculations.
Treatments consisted of (1) an i.m. dose of 25 mg 
of PGF2α (5 mL of Lutalyse Sterile Solution, Zoetis) 
on d 7 with FTAI 72 ± 2 h later (control); (2) an i.m. 
dose of 100 μg of GnRH (2 mL of Factrel injection) on 
d 0, on d 7 a dose of 25 mg of PGF2α, and each site 
selected to administer the second administration of 100 
μg of GnRH (T100) on d 9 at either 48 ± 2 h after 
PGF2α with FTAI 24 ± 2 h later (d 10) or 56 ± 2 h 
after PGF2α with FTAI 17 ± 2 h later (d 10); (3) same 
timing of the treatment regimen as T100 with both 
administrations of 150 μg of GnRH (3 mL of Factrel 
injection; T150); and (4) same timing of the treatment 
regimen as T100 with both administrations of 200 μg 
of GnRH (4 mL of Factrel injection; T200). Three sites 
selected the earlier timing of the second administration 
of all GnRH treatments and 3 sites selected the later 
timing; both treatment options were considered repre-
sentative of FTAI treatment regimens.
Following treatment initiation, cows were observed 
at least once daily for signs of estrus and for abnor-
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mal clinical signs. Cows observed in estrus before d 13 
were not inseminated, except for FTAI on d 10. Cows 
observed in estrus on d 13 or later were inseminated, 
completed the study that day, and were classified as not 
pregnant for statistical analyses. Cows with abnormal 
clinical signs were treated following site-specific treat-
ment prescriptions.
Cows were AI by personnel normally conducting AI 
following site-specific procedures. Early pregnancy di-
agnosis was conducted only if this was a site-specific 
procedure and no sooner than 27 d after insemination. 
Cows found not pregnant completed the study that day 
and were classified as not pregnant to FTAI. All cows 
found to be pregnant to early pregnancy diagnosis and 
those cows not returning to estrus had a final pregnancy 
diagnosis conducted during the interval of 42 and 65 d 
post-FTAI. However, within a site, all final pregnancy 
diagnoses were conducted within a 7-d interval, such as 
during 45 ± 3 d after FTAI.
Statistical Analyses
P/FTAI. The response for effectiveness was P/
FTAI calculated as [(number of cows pregnant at final 
pregnancy diagnosis)/(number of cows inseminated at 
FTAI – number of cows removed from analysis)] × 100. 
Cow was the experimental unit. Pregnancy per FTAI 
was analyzed as a binary variable (1 = pregnant, 0 = 
not pregnant) using a generalized linear mixed model 
with a binomial error distribution and a logit link func-
tion. The statistical model included fixed effects for 
treatment and random effects of site, site by treatment, 
enrollment cohort within site, and residual. The model 
included parity (first parity vs. second and greater) as 
a covariate. The term used for testing treatment dif-
ferences was the site by treatment interaction. Timing 
for the second administration of GnRH HCl, either 48 
or 56 h after PGF2α, was not included in the model 
because this was confounded with site. No comparisons 
were made between these treatment regimen options. 
Least squares means, standard errors, and 95% con-
fidence intervals were constructed. Back-transformed 
least squares means and back-transformed 95% confi-
dence intervals are reported unless otherwise stated. 
For demonstration of effectiveness, an α = 0.05 and a 
2-tailed test were used.
Field Safety. Safety data were summarized using 
the VeDDRA system for organ classifications but not 
analyzed.
RESULTS AND DISCUSSION
Between 188 and 195 cows were enrolled at the 6 sites 
with a total enrollment of 1,142 cows. Twenty-three 
cows were removed from the study because of signifi-
cant noncompliance with protocol (deviations), includ-
ing incorrect treatment administration, administration 
of hormonal products or AI by farm personnel outside 
the protocol, incorrect allotment, and so on. Another 
29 cows were removed from the study because of injury, 
illness, culling, death, or other reasons. Data from these 
52 cows were included in summaries and analyses up to 
the day of the deviation or removal; extraneous data 
collected beyond this day were removed from summa-
ries and analyses data set.
P/FTAI
Included in the statistical analyses were 1,090 cows 
for P/FTAI, with 370 first parity cows (33.9%) and 
720 cows in second or greater parity (66.1%). The P/
FTAI and total cows included in statistical analyses, 
summarized by site and treatment, can be found in 
Table 1. Back-transformed treatment group least 
squares means for P/FTAI were 17.1, 27.3, 29.1, and 
32.2% for control, T100, T150, and T200, respectively 
(Table 2). The P/FTAI was greater (P ≤ 0.0123) in 
each GnRH HCl treatment dose than for the control. 
Summed across sites, the P/FTAI in first parity cows 
was 25.4% (94/370) and in second or greater parity 
cows was 28.75% (207/720); parity did not have a sig-
nificant effect (P = 0.36) on P/FTAI. These P/FTAI 
to the Ovsynch program are within the range reported 
by others; Stevenson et al. (1999) reported a 22.1% (ex-
periment 1) and 35.6% (experiment 2) P/FTAI, Jobst 
et al. (2000) reported 30.1% P/FTAI, and Pursley et al. 
(1997) reported 37% P/FTAI.
This improvement in P/FTAI in the GnRH HCl 
treatments relative to control was expected. The con-
trol, consisting of a single administration of PGF2α with 
FTAI 72 h later, would not be expected to synchronize 
ovulation in cows in the first 5 d of the estrous cycle, 
and the estrus in some cows responding to PGF2α 
treatment would be before or after the FTAI at 72 h, 
resulting in reduced fertility. In the Ovsynch treatment 
regimen, the LH released in response to the first injec-
tion of GnRH results in ovulation of any large follicles 
present on the ovary. This is followed by the recruit-
ment and development of a new follicle that is expected 
to ovulate in response to the LH released following the 
second injection of GnRH. The PGF2α is administered 
to initiate the luteolytic process, resulting in regression 
of corpora lutea present on ovaries. The FTAI is sched-
uled, relative to the second administration of GnRH, 
to optimize conception. Furthermore, P/FTAI can be 
increased by inclusion of hormonal treatment programs 
administered before the Ovsynch protocol. Such pro-
grams are designed to have cows at the ideal time of 
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the estrous cycle to maximize ovulation response to the 
first GnRH administered in the Ovsynch protocol. One 
program, commonly called Presynch, uses 2 injections 
of PGF2α at a 14-d interval, with the second injection 
administered 10 to 14 d before initiation of Ovsynch 
protocol (Moreira et al., 2001; El-Zarkouny et al., 2004). 
An alternate program is the double-Ovsynch protocol. 
This program consists of a pre-Ovsynch program with 
no FTAI and the second administration of GnRH 7 
d before initiation of a regular 56-h breeding-Ovsynch 
program (Souza et al., 2008).
Differences in P/FTAI between GnRH HCl doses 
were small, 1.8 to 4.9 percentage points, and no differ-
ences were detected (T100 vs. T150, P = 0.67; T100 vs. 
T200, P = 0.26; T150 vs. T200, P = 0.47). Thus, no 
significant effect on P/FTAI was detected by increasing 
the dose of GnRH from 100 to 200 μg. However, the 
current study was not designed with sufficient power 
to detect potentially small differences in P/FTAI be-
tween GnRH doses as has been documented in other 
studies. Fricke et al. (1998) reported that cows admin-
istered 50 μg of GnRH diacetate tetrahydrate for both 
administrations of GnRH had synchronized ovulation 
response to the second dose of an Ovsynch treatment 
regimen not different from that of cows administered 
100 μg (84.9 vs. 83.1%), respectively. In addition, P/
FTAI at 56 d after FTAI were not different, at 39.6 vs. 
40.7%, respectively. Giordano et al. (2012) reported LH 
response to doses of 100 and 200 μg of GnRH diacetate 
tetrahydrate to dairy cows in either a high- or low-
progesterone status. The LH response was greater in 
cows administered 200 μg in either progesterone status, 
though lower concentrations of LH were observed in 
cows in the high-progesterone status regardless of dose. 
In addition, Giordano et al. (2013) evaluated the effect 
of increasing the dose of GnRH diacetate tetrahydrate 
from 100 to 200 μg for the first administration of GnRH 
in the breeding-Ovsynch part of a double-Ovsynch 
FTAI protocol. Ovulation response was greater (P = 
0.01) in cows administered 200 μg compared with cows 
administered 100 μg (66.6 vs. 57.5%, respectively); 
however, no difference was detected in P/FTAI (40.8 
vs. 34.6%) at 74 d after FTAI.
These data suggest that, although LH release from 
the pituitary and incidence of ovulation both increase 
in response to doses of GnRH greater than 100 μg, P/
Table 1. Percentage of cows pregnant to fixed-time AI (FTAI) and total cows by site and treatment 
Site
Experimental group
Total pregnantControl1 pregnant T1002 pregnant T1503 pregnant T2004 pregnant
% n % n % n % n % n
A 21.7 46 33.3 45 50.0 44 41.7 48 36.6 183
B 9.1 44 26.0 50 31.3 48 32.6 46 25.0 188
C 17.8 45 40.9 44 18.2 44 31.8 44 27.1 177
D 18.2 44 11.1 45 25.6 43 28.3 46 20.8 178
E 21.7 46 30.4 46 34.0 47 34.1 44 30.1 183
F 19.5 41 29.8 47 22.9 48 31.1 45 26.0 181
Total 18.0 266 28.5 277 30.3 274 33.3 273 27.6 1,090
1Control was a single dose of 25 mg of PGF2α with FTAI 72 ± 2 h later.
2T100 was a dose of 100 μg of GnRH on d 0, a dose of 25 mg of PGF2α on d 7, a second dose of GnRH either 48 ± 2 h after PGF2α administra-
tion with FTAI 24 ± 2 h after GnRH or 56 ± 2 h after PGF2α with FTAI 17 ± 2 h after second dose of GnRH.
3T150 was the same as T100 with 150 μg of GnRH for both doses.
4T200 was the same as T100 with 200 μg of GnRH for both doses.
Table 2. Percentage of cows pregnant to fixed-time AI (FTAI) presented as back-transformed LSM with 95% CI and probability of difference 
between each GnRH dose and control 
Treatment1 Animals (n) LSM SE Lower 95% CI Upper 95% CI P-value2
Control 266 17.1 2.6 12.4 23.1  
T100 277 27.3 3.2 21.0 34.6 0.0123
T150 274 29.1 3.3 22.5 36.6 0.0051
T200 273 32.2 3.4 25.3 39.9 0.0011
1Control was a single dose of 25 mg of PGF2α with FTAI 72 ± 2 h later; T100 was a dose of 100 μg of GnRH on d 0, a dose of 25 mg of PGF2α 
on d 7, a second dose of GnRH either 48 ± 2 h after PGF2α administration with FTAI 24 ± 2 h after GnRH or 56 ± 2 h after PGF2α with FTAI 
17 ± 2 h after second dose of GnRH; T150 was the same as T100 with 150 μg of GnRH for both doses; T200 was the same as T100 with 200 
μg of GnRH for both doses.
2P-value for comparison of treatment within row with control.
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FTAI is not increased to doses up to 200 μg. In addi-
tion, response to 50 μg of GnRH diacetate tetrahydrate 
was similar to that of 100 μg, as measured by ovulation 
response or P/FTAI. In toto, these data support that 
under a variety of Ovsynch programs 100 μg of GnRH 
is on a plateau of the dose response curve as measured 
by P/FTAI.
Field Safety
No abnormal clinical signs were attributed to treat-
ment administration. Of the abnormal clinical signs 
documented over all sites, mastitis (n = 88), lameness 
(n = 21), and pneumonia (n = 9) had the greatest inci-
dence of occurrence, representing 62.0, 14.8, and 6.3% 
of all abnormal clinical signs documented, respectively. 
These are common clinical conditions for dairy cows 
at this stage of lactation and are not considered to be 
treatment related.
An adverse health event was documented in 118 cows, 
with 26, 30, 27, and 35 cows in control, T100, T150, and 
T200, respectively. Therefore, no apparent trends were 
observed in the incidence of abnormal clinical signs de-
tected as the dose of GnRH HCl increased. Of these 118 
cows, only 88 had a determination of pregnancy status, 
the remaining being removed from the study. For these 
88 cows, the mean P/FTAI were 29.4, 16.7, 23.8, and 
46.2% for control (n = 17), T100 (n = 24), T150 (n = 
21), and T200 (n = 26), respectively, and 29.5% over 
all. A total of 15, 23, 17, and 20 cows in control, T100, 
T150, and T200, respectively, were documented with 
mastitis, with only 12, 19, 14, and 17 of these cows with 
a determination of pregnancy status, the remaining be-
ing removed from the study. These cows had mean P/
FTAI of 41.7, 10.5, 21.4, and 52.9%, respectively, and 
30.6% overall. These data should be interpreted with 
caution because cows removed from the study were not 
included in these mean P/FTAI calculations and the 
reason cows were removed may have been as a conse-
quence of an adverse health event. Therefore, these P/
FTAI may be inflated. In contrast, 1,002 cows did not 
have any adverse health event documented. These cows 
had a mean P/FTAI of 17.3, 29.6, 30.8, and 32.0% for 
control, T100, T150, and T200, respectively, and 27.4% 
overall.
CONCLUSIONS
Dairy cows administered 100, 150, or 200 μg of 
GnRH as the HCl salt in Ovsynch FTAI programs had 
P/FTAI greater than that of cows administered PGF2α 
with FTAI 72 h later. Under the conditions of the cur-
rent study, increasing the dose of GnRH from 100 to 
200 μg had no detected effect on P/FTAI. No abnormal 
clinical signs were observed that were attributed to 
treatment with GnRH HCl at doses ≤200 μg of GnRH. 
These data support the effectiveness and field safety of 
the use of 100 to 200 μg of GnRH, as the HCl salt in 
the Ovsynch FTAI protocol in lactating dairy cows as 
measured by P/FTAI and incidence of abnormal health 
events.
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